VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
VALNValneva SE
$5.38$463M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksVALNP/E History

VALN logoValneva SE (VALN) P/E Ratio History

Deep Value

Trading at -3.6x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2021–2023

Current P/E (TTM)
-3.6x
-113% vs 5Y avg
5Y Avg P/E
28.0x
Median 35.1x
5Y Percentile
0th
Lower end of range
PEG Ratio
N/A
5-Year P/E Range
-3.6x
Min7.5xMedian35.1xMax37.1x
TTM EPS$-1.60
Price$5.38
Earnings YieldN/A
EPS Growth (1Y)-676.5%
EPS Growth (5Y)N/A

Loading P/E history...

P/E Ratio Analysis

As of June 21, 2026, Valneva SE (VALN) trades at a price-to-earnings ratio of -3.6x, with a stock price of $5.38 and trailing twelve-month earnings per share of $-1.60.

The current P/E is 113% below its 5-year average of 28.0x. Over the past five years, VALN's P/E has ranged from a low of 7.5x to a high of 37.1x, placing the current valuation at the 0th percentile of its historical range.

Compared to the Healthcare sector median P/E of 22.1x, VALN trades at a 116% discount to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.

Relative to the broader market, VALN trades at a notable discount to the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our VALN DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

VALN Cross-Benchmark Valuation

How does the current P/E compare to sector peers and the broader market?

vs. Healthcare
-3.6vs22.1
-116%
Below Sector
vs. S&P 500
-3.6vs24.4
-115%
Below Market
PEG Analysis
N/A
P/E ÷ EPS Growth
Based on -676% EPS growth (1Y)

VALN P/E vs Peers

Vaccines and Infectious Disease peers sorted by market cap

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
NVAX logoNVAXNovavax, Inc.
$2B3.6Lowest-+307%
SIGA logoSIGASIGA Technologies, Inc.
$310M13.1--60%
PFE logoPFEPfizer Inc.
$143B18.5--4%
MRK logoMRKMerck & Co., Inc.
$281B15.60.74+8%
GSK logoGSKGSK plc
$102B6.90.49Best+348%Best
SNY logoSNYSanofi
$102B18.2--7%

Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.

VALN Historical P/E Data (2021–2023)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterPeriod EndPriceTTM EPSP/E Ratiovs Avg
FY2023 Q2Jun 30 2023$14.75$0.4235.1x+25%
FY2022 Q3Sep 30 2022$10.10$1.347.5x-73%
FY2022 Q1-$34.30$1.0632.4x+15%
FY2021 Q4Dec 31 2021$55.51$1.5037.1x+32%

Average P/E for displayed period: 28.0x

Export Data
Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

5+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

VALN — Frequently Asked Questions

Quick answers to the most common questions about buying VALN stock.

What is VALN's P/E ratio?

Valneva SE (VALN) trailing twelve-month P/E ratio is -3.6x, based on TTM diluted EPS of $-1.60. The 5-year average P/E is 28.0x and the historical range spans 7.5x to 37.1x.

Is VALN stock overvalued or undervalued?

VALN trades at -3.6x P/E, below its 5-year average of 28.0x. At the 0th percentile of its historical range (7.5x–37.1x), the stock is priced at a discount to its own history.

Is VALN stock expensive?

No, VALN is not expensive on a historical basis. The current P/E of -3.6x is below the 5-year average of 28.0x and sits at the 0th percentile of its valuation range.

What is VALN's historical P/E range?

Over the past 5 years, VALN's P/E ratio has ranged from 7.5x to 37.1x, with a median of 35.1x and an average of 28.0x. The current P/E of -3.6x places the stock at the 0th percentile of this range. Full historical data spans 2021–2023.

How does VALN's P/E compare to the S&P 500?

VALN trades at -3.6x P/E versus the S&P 500 median of 24.4x. The 115% discount to the market suggests lower growth expectations or perceived higher risk.

How does VALN's valuation compare to Healthcare peers?

Valneva SE P/E of -3.6x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.

What is VALN's PEG ratio?

VALN PEG ratio is N/A, based on a P/E of -3.6x and EPS growth of -676.5%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.

What is VALN's earnings yield?

VALN earnings yield is N/A, the inverse of its -3.6x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.

VALN P/E Ratio History (2021–2023)

Quarterly valuation multiple from closing price and trailing EPS

Current35.1x
Period Avg28.0x
Range7.5x - 37.1x
Change-5%
4 quartersDec 31, 2021 - Jun 30, 2023